ENDPOINTS

Immuneering reports Phase 2a MEK pill data in first-line pancreatic cancer

Immuneering’s oral MEK inhibitor allowed 94% of pancreatic cancer patients in a Phase 2a trial to survive six months when used first line in combination with chemotherapy, the company said Tuesday. Atebimetinib (formerly IMM-1-104) is ...

Jun 17, 2025 - 11:10
 0
Immuneering reports Phase 2a MEK pill data in first-line pancreatic cancer
Immuneering’s oral MEK inhibitor allowed 94% of pancreatic cancer patients in a Phase 2a trial to survive six months when used first line in combination with chemotherapy, the company said Tuesday. Atebimetinib (formerly IMM-1-104) is ...
Read More

Tags:

Previous Article

50 years later, Apollo 17’s moon samples are still revealing secrets about lunar...

Next Article

‘An economic necessity’: 6 leaders on why gender parity can’t wait

Related Posts

Trump administration removes all members of CDC vaccine board

Trump administration removes all members of CDC vaccine...

Jun 9, 2025  0

A new dawn for psychedelics? Compass could be the first to find out

A new dawn for psychedelics? Compass could be the first...

May 28, 2025  0

Intellia reports case of liver toxicity in ATTR gene editing study

Intellia reports case of liver toxicity in ATTR gene ed...

May 29, 2025  0